UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 912

Sortiert nach

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

American journal of transplantation, 2013-06, Vol.13 (6), p.1601-1605

2013

Volltextzugriff (PDF)

Alterations in amino acid status in cats with feline dysautonomia

PloS one, 2017-03, Vol.12 (3), p.e0174346-e0174346

2017

Volltextzugriff (PDF)

O7 ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0–2: COSMOS STUDY SUBGROUP ANALYSIS

Journal of hepatology, 2014-04, Vol.60 (1), p.S4-S4

2014

Volltextzugriff (PDF)

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR)

Journal of viral hepatitis, 2013-10, Vol.20 (10), p.699-707

2013

Volltextzugriff (PDF)

1217 VIROLOGICAL ANALYSIS OF HCV GENOTYPE 1 PATIENT SAMPLES FROM THE PROTON STUDY

Journal of hepatology, 2012-04, Vol.56, p.S483-S483

2012

Volltextzugriff (PDF)

P1171 INTEGRATED SAFETY ANALYSIS OF SOFOSBUVIR-BASED HCV TREATMENT REGIMENS FROM PHASE 3 STUDIES

Journal of hepatology, 2014-04, Vol.60 (1), p.S475-S475

2014

Volltextzugriff (PDF)

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

Hepatology (Baltimore, Md.), 2015-05, Vol.61 (5), p.1485-1494

2015

Volltextzugriff (PDF)

1428 INVERSE CHANGES IN HEPATIC EXPRESSION OF INTERFERON LAMBDA AND ALPHA AND IFNL4 GENOTYPE ARE ASSOCIATED WITH TREATMENT RESPONSE IN SOFOSBUVIR/RIBAVIRIN TREATED HCV GENOTYPE-1 SUBJECTS

Journal of hepatology, 2013-04, Vol.58, p.S575-S576

2013

Volltextzugriff (PDF)

1 ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPY

Journal of hepatology, 2013-04, Vol.58, p.S1-S1

2013

Volltextzugriff (PDF)

Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males

Antimicrobial Agents and Chemotherapy, 2001-02, Vol.45 (2), p.502-508

2001

Volltextzugriff (PDF)

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

Journal of hepatology, 2013-04, Vol.58, p.S570-S570

2013

Volltextzugriff (PDF)

1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA <LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY)

Journal of hepatology, 2011-03, Vol.54, p.S543-S543

2011

Volltextzugriff (PDF)

1235 PSI-352938, A NOVEL PURINE NUCLEOTIDE ANALOG, EXHIBITS POTENT ANTIVIRAL ACTIVITY AND NO EVIDENCE OF RESISTANCE IN PATIENTS WITH HCV GENOTYPE 1 OVER 7 DAYS

Journal of hepatology, 2011-03, Vol.54, p.S488-S488

2011

Volltextzugriff (PDF)

Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System

Antimicrobial Agents and Chemotherapy, 2002-02, Vol.46 (2), p.464-470

2002

Volltextzugriff (PDF)

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults

Antimicrobial Agents and Chemotherapy, 2000-08, Vol.44 (8), p.2061-2067

2000

Volltextzugriff (PDF)

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

The New England journal of medicine, 2014-05, Vol.370 (21), p.1993-2001

2014

Volltextzugriff (PDF)

61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3

Journal of hepatology, 2011-03, Vol.54, p.S28-S28

2011

Volltextzugriff (PDF)

Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers

Antimicrobial Agents and Chemotherapy, 2000-04, Vol.44 (4), p.978-984

2000

Volltextzugriff (PDF)

Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase

Journal of viral hepatitis, 2008-08, Vol.15 (8), p.571-577

2008

Volltextzugriff (PDF)

Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir

Antimicrobial Agents and Chemotherapy, 2000-06, Vol.44 (6), p.1655-1659

2000

Volltextzugriff (PDF)

750 NON-INVASIVE SERUM BIOMARKER DEVELOPMENT USING HIGH THROUGHPUT MULTIPLEX PROTEIN DETECTION ASSAY IN CHRONIC HEPATITIS C PATIENTS AND COMPARISON TO FIBROSURE

Journal of hepatology, 2008, Vol.48, p.S280-S280

2008

Volltextzugriff (PDF)

In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours

Antimicrobial Agents and Chemotherapy, 2003-11, Vol.47 (11), p.3393-3399

2003

Volltextzugriff (PDF)

Response of ornamental Eucalyptus from acidic and alkaline habitats to potting medium pH

Scientia horticulturae, 2001-04, Vol.88 (2), p.121-131

2001

Volltextzugriff (PDF)

Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy Men

Pharmacotherapy, 1999-12, Vol.19 (12), p.1378-1384

1999

Volltextzugriff (PDF)

1 – 25 von 912

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(759)
Mit Volltextzugriff
(814)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

Alterations in amino acid status in cats with feline dysautonomia

O7 ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0–2: COSMOS STUDY SUBGROUP ANALYSIS

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR)

1217 VIROLOGICAL ANALYSIS OF HCV GENOTYPE 1 PATIENT SAMPLES FROM THE PROTON STUDY

P1171 INTEGRATED SAFETY ANALYSIS OF SOFOSBUVIR-BASED HCV TREATMENT REGIMENS FROM PHASE 3 STUDIES

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation

1428 INVERSE CHANGES IN HEPATIC EXPRESSION OF INTERFERON LAMBDA AND ALPHA AND IFNL4 GENOTYPE ARE ASSOCIATED WITH TREATMENT RESPONSE IN SOFOSBUVIR/RIBAVIRIN TREATED HCV GENOTYPE-1 SUBJECTS

1 ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPY

Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males

1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)

1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA <LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY)

1235 PSI-352938, A NOVEL PURINE NUCLEOTIDE ANALOG, EXHIBITS POTENT ANTIVIRAL ACTIVITY AND NO EVIDENCE OF RESISTANCE IN PATIENTS WITH HCV GENOTYPE 1 OVER 7 DAYS

Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System

Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3

Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers

Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase

Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir

750 NON-INVASIVE SERUM BIOMARKER DEVELOPMENT USING HIGH THROUGHPUT MULTIPLEX PROTEIN DETECTION ASSAY IN CHRONIC HEPATITIS C PATIENTS AND COMPARISON TO FIBROSURE

In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours

Response of ornamental Eucalyptus from acidic and alkaline habitats to potting medium pH

Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy Men

Suchergebnisse filtern